Anabolic therapies

Nancy E Lane, Stuart L. Silverman

Research output: Contribution to journalArticle

22 Scopus citations


The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalCurrent Osteoporosis Reports
Issue number1
StatePublished - Mar 2010


  • BMD
  • BMP
  • Osteoporosis
  • PTH
  • Sclerostin
  • Wnt

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Anabolic therapies'. Together they form a unique fingerprint.

  • Cite this